Checkpoint Therapeutics (CKPT) to Release Earnings on Friday

Checkpoint Therapeutics (NASDAQ:CKPT - Get Free Report) is expected to post its quarterly earnings results before the market opens on Friday, March 28th. Analysts expect Checkpoint Therapeutics to post earnings of ($0.22) per share for the quarter.

Checkpoint Therapeutics Trading Down 0.5 %

CKPT traded down $0.02 during mid-day trading on Monday, hitting $4.05. 864,241 shares of the stock were exchanged, compared to its average volume of 1,114,617. The company has a market cap of $197.77 million, a PE ratio of -2.20 and a beta of 1.41. The firm's fifty day moving average is $3.24 and its two-hundred day moving average is $3.20. Checkpoint Therapeutics has a 1-year low of $1.38 and a 1-year high of $4.50.

Insider Buying and Selling

In other Checkpoint Therapeutics news, CEO James F. Oliviero III sold 10,331 shares of the stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $3.15, for a total value of $32,542.65. Following the transaction, the chief executive officer now directly owns 3,775,019 shares in the company, valued at $11,891,309.85. This represents a 0.27 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO William Garrett Gray sold 74,110 shares of the firm's stock in a transaction that occurred on Thursday, February 6th. The stock was sold at an average price of $3.67, for a total transaction of $271,983.70. Following the sale, the chief financial officer now directly owns 1,458,644 shares in the company, valued at approximately $5,353,223.48. The trade was a 4.84 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 93,674 shares of company stock worth $336,011 over the last 90 days. 2.10% of the stock is owned by insiders.

Remove Ads

Analyst Ratings Changes

Several research analysts have recently commented on CKPT shares. Lake Street Capital reissued a "hold" rating and issued a $4.10 price objective (down previously from $7.00) on shares of Checkpoint Therapeutics in a research note on Monday, March 10th. HC Wainwright restated a "neutral" rating and issued a $4.10 price target on shares of Checkpoint Therapeutics in a research note on Tuesday, March 11th. Finally, D. Boral Capital reiterated a "buy" rating and issued a $4.80 price objective (down from $9.00) on shares of Checkpoint Therapeutics in a research note on Monday, March 10th.

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.